Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
N Engl J Med
.
2022 Feb 3;386(5):494-496.
doi: 10.1056/NEJMc2119270.
Epub 2021 Dec 29.
Authors
Shirley Collie
1
,
Jared Champion
1
,
Harry Moultrie
2
,
Linda-Gail Bekker
3
,
Glenda Gray
4
Affiliations
1
Discovery Health, Johannesburg, South Africa.
2
National Institute of Communicable Diseases, Johannesburg, South Africa.
3
Desmond Tutu HIV Foundation, Cape Town, South Africa.
4
South African Medical Research Council, Cape Town, South Africa glenda.gray@mrc.ac.za.
PMID:
34965358
PMCID:
PMC8757569
DOI:
10.1056/NEJMc2119270
No abstract available
Publication types
Letter
MeSH terms
BNT162 Vaccine*
Humans
Logistic Models
SARS-CoV-2*
South Africa
Vaccine Efficacy*
Substances
BNT162 Vaccine
Supplementary concepts
SARS-CoV-2 variants